Details for New Drug Application (NDA): 206066
✉ Email this page to a colleague
NDA 206066 describes BEPOTASTINE BESILATE, which is a drug marketed by Alembic, Apotex, Mylan, and Somerset Theraps Llc, and is included in four NDAs. It is available from four suppliers. Additional details are available on the BEPOTASTINE BESILATE profile page.
The generic ingredient in BEPOTASTINE BESILATE is bepotastine besilate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.
The generic ingredient in BEPOTASTINE BESILATE is bepotastine besilate. There are seven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the bepotastine besilate profile page.
Summary for 206066
| Tradename: | BEPOTASTINE BESILATE |
| Applicant: | Apotex |
| Ingredient: | bepotastine besilate |
| Patents: | 0 |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION/DROPS;OPHTHALMIC | Strength | 1.5% | ||||
| Approval Date: | Mar 5, 2019 | TE: | AT | RLD: | No | ||||
Complete Access Available with Subscription
